SCHEMBL4314480

SCHEMBL4314480

CCN(CC)CCOc1ccc([N+](=O)[O-])c(C=Cc2n[nH]c3ccccc23)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 2/20 0.39
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
KCNH2 Q12809 1/20 0.37
KDR P35968 2/20 0.37
MAPT P10636 3/20 0.37
CHRNA7 P36544 1/20 0.36
KMT2A Q03164 1/20 0.36
SIRT5 Q9NXA8 1/20 0.36
LMNA P02545 1/20 0.36
CHEK1 O14757 1/20 0.36
FGFR1 P11362 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
BACE1 P56817 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4314474 1.00 ALK (0.39) ALKAURKAAURKBBCHEACHE
SCHEMBL4313807 0.84 LMNA (0.39) ALKAURKBACHEKDRMAPT
SCHEMBL4313814 0.84 LMNA (0.39) ALKAURKBACHEKDRMAPT
SCHEMBL4315162 0.79 KDR (0.41) AURKAAURKBSMN1; SMN2KDRMAPT
SCHEMBL4315155 0.79 KDR (0.41) AURKAAURKBSMN1; SMN2KDRMAPT
SCHEMBL4311237 0.79 KDM4E (0.50) AURKAAURKBSMN1; SMN2KDRMAPT
SCHEMBL4321132 0.79 KDM4E (0.50) AURKAAURKBSMN1; SMN2KDRMAPT
Hydrochloric Acid SCHEMBL5693151 0.78 MCHR1 (0.47) BCHEACHEKDRCHEK1FGFR1
Hydrochloric Acid SCHEMBL5693148 0.78 MCHR1 (0.47) BCHEACHEKDRCHEK1FGFR1
SCHEMBL4321978 0.78 MAPT (0.41) BCHEACHESMN1; SMN2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101111483-B IGF-1R inhibitors KYOWA HAKKO KIRIN CO.,LTD. (JP) 2011-12-14 CN disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
CN-101111483-A IGF-1R inhibitors KYOWA HAKKO KOGYO KK (JP) 2008-01-23 CN disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 ALK 321/4885AURKA 3687/4885AURKB 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.